Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a Β-galactosidase-activatable prodrug seco-analog of duocarmycin SA

Cancer Gene Therapy

Volumn 18, Issue 1, 2011, Pages 42-52

  Seubert, C M ^a   Stritzker, J ^a,b   Hess, M ^a   Donat, U ^a   Sturm, J B ^a   Chen, N ^b   Hof, J M V ^c   Krewer, B ^c   Tietze, L F ^c   Gentschev, I ^a,b   Szalay, A A ^a,b,d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b GENELUX CORPORATION   (United States)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

breast cancer; oncolytic virotherapy; prodrug; vaccinia virus

Indexed keywords

BETA GALACTOSIDASE; DUOCARMYCIN SA;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER THERAPY; CELL KILLING; CONTROLLED STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; VACCINIA VIRUS; VIRUS STRAIN; XENOGRAFT;

ANIMALS; BETA-GALACTOSIDASE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; INDOLES; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; ONCOLYTIC VIROTHERAPY; PRODRUGS; PYRROLES; VACCINIA VIRUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

GIARDIA LAMBLIA VIRUS; MUS; VACCINIA VIRUS;

EID: 78650309660     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.49     Document Type: Article

References (45)

1. Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2004; CD002748.
2. American Cancer Society. Cancer facts and figures 2009. 2009. http://www.cancer.org.
3. Kumar S, Gao L, Yeagy B, Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008; 10: 371-379.
4. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254: 178-216.
5. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996; 93: 11341-11348.
6. Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000; 7: 66-73.
7. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 2007; 67: 10038-10046.
8. Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004; 22: 313-320.
9. Schepelmann S, Springer CJ. Viral vectors for gene-directed enzyme prodrug therapy. Curr Gene Ther 2006; 6: 647-670.
10. Chalikonda S, Kivlen MH, O'Malley ME, Eric Dong XD, McCart JA, Gorry MC et al. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther 2008; 15: 115-125.
11. Erbs P, Findeli A, Kintz J, Cordier P, Hoffmann C, Geist M et al. Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ther 2008; 15: 18-28.
12. Foloppe J, Kintz J, Futin N, Findeli A, Cordier P, Schlesinger Y et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 2008; 15: 1361-1371.
13. Gnant MF, Puhlmann M, Alexander Jr HR, Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res 1999; 59: 3396-3403.
14. McCart JA, Puhlmann M, Lee J, Hu Y, Libutti SK, Alexander HR et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther 2000; 7: 1217-1223.
15. Puumalainen AM, Vapalahti M, Agrawal RS, Kossila M, Laukkanen J, Lehtolainen P et al. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 1998; 9: 1769-1774.
16. Griscelli F, Opolon P, Saulnier P, Mami-Chouaib F, Gautier E, Echchakir H et al. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther 2003; 10: 386-395.
17. Tung CH, Zeng Q, Shah K, Kim DE, Schellingerhout D, Weissleder R. In vivo imaging of beta-galactosidase activity using far red fluorescent switch. Cancer Res 2004; 64: 1579-1583.
18. Josserand V, Texier-Nogues I, Huber P, Favrot MC, Coll JL. Non-invasive in vivo optical imaging of the lacZ and luc gene expression in mice. Gene Ther 2007; 14: 1587-1593.
19. Wehrman TS, von Degenfeld G, Krutzik PO, Nolan GP, Blau HM. Luminescent imaging of beta-galactosidase activity in living subjects using sequential reporter-enzyme luminescence. Nat Methods 2006; 3: 295-301.
20. Lee KH, Byun SS, Choi JH, Paik JY, Choe YS, Kim BT. Targeting of lacZ reporter gene expression with radioiodine-labelled phenylethyl-beta-d- thiogalactopyranoside. Eur J Nucl Med Mol Imaging 2004; 31: 433-438.
21. Louie AY, Huber MM, Ahrens ET, Rothbacher U, Moats R, Jacobs RE et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000; 18: 321-325.
22. Tietze LF, Krewer B. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies. Anticancer Agents Med Chem 2009; 9: 304-325.
23. Tietze LF, von Hof JM, Krewer B, Muller M, Major F, Schuster HJ et al. Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy. ChemMedChem 2008; 3: 1946-1955.
24. Stritzker J, Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, Szalay AA. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol 2007; 297: 151-162.
25. Hirota M, Fujiwara T, Mineshita S, Sugiyama H, Teraoka H. Distamycin A enhances the cytotoxicity of duocarmycin A and suppresses duocarmycin A-induced apoptosis in human lung carcinoma cells. Int J Biochem Cell Biol 2007; 39: 988-996.
26. Tada-Oikawa S, Oikawa S, Kawanishi M, Yamada M, Kawanishi S. Generation of hydrogen peroxide precedes loss of mitochondrial membrane potential during DNA alkyla-tion-induced apoptosis. FEBS Lett 1999; 442: 65-69.
27. Wrasidlo W, Johnson DS, Boger DL. Induction of endonucleolytic DNA fragmentation and apoptosis by the duocarmycins. Bioorg Med Chem Lett 1994; 4: 631-636.
28. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376: 37-43.
29. Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004; 53: 153-159.
30. Kim R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 2005; 103: 1551-1560.
31. Taylor JM, Barry M. Near death experiences: poxvirus regulation of apoptotic death. Virology 2006; 344: 139-150.
32. Hurst J, Maniar N, Tombarkiewicz J, Lucas F, Roberson C, Steplewski Z et al. A novel model of a metastatic human breast tumour xenograft line. Br J Cancer 1993; 68: 274-276.
33. Rathinavelu P, Malave A, Raney SR, Hurst J, Roberson CT, Rathinavelu A. Expression of mdm-2 oncoprotein in the primary and metastatic sites of mammary tumor (GI-101) implanted athymic nude mice. Cancer Biochem Biophys 1999; 17: 133-146.
34. Gentschev I, Stritzker J, Hofmann E, Weibel S, Yu YA, Chen N et al. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. Cancer Gene Ther 2009; 16: 320-328.
35. Boger DL, Johnson DS, Yun W, Tarby CM. Molecular basis for sequence selective DNA alkylation by (+)- and ent-(-)-CC-1065 and related agents: alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity. Bioorg Med Chem 1994; 2: 115-135.
36. Taylor JM, Quilty D, Banadyga L, Barry M. The vaccinia virus protein F1 L interacts with Bim and inhibits activation of the pro-apoptotic protein Bax. J Biol Chem 2006; 281: 39728-39739.
37. Stewart TL, Wasilenko ST, Barry M. Vaccinia virus F1L protein is a tail-anchored protein that functions at the mitochondria to inhibit apoptosis. J Virol 2005; 79: 1084-1098.
38. Wasilenko ST, Banadyga L, Bond D, Barry M. The vaccinia virus F1L protein interacts with the proapoptotic protein Bak and inhibits Bak activation. J Virol 2005; 79: 14031-14043.
39. Wasilenko ST, Meyers AF, Vander Helm K, Barry M. Vaccinia virus infection disarms the mitochondrion-mediated pathway of the apoptotic cascade by modulating the permeability transition pore. J Virol 2001; 75: 11437-11448.
40. Wasilenko ST, Stewart TL, Meyers AF, Barry M. Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis. Proc Natl Acad Sci USA 2003; 100: 14345-14350.
41. Kelly KJ, Brader P, Woo Y, Li S, Chen N, Yu YA et al. Real-time intraoperative detection of melanoma lymph node metastases using recombinant vaccinia virus GLV-1h68 in an immunocompetent animal model. Int J Cancer 2009; 124: 911-918.
42. Gentschev I, Hofmann E, Donat U, Weibel S, Adelfinger M, Raab V et al. Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68. J Biomed Biotechnol 2010; e-pub ahead of print 23 June 2010; doi:10.1155/2010/736907.
43. Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S et al. Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics 2009; 10: 301.
44. Worschech A, Haddad D, Stroncek DF, Wang E, Marincola FM, Szalay AA. The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother 2009; 58: 1355-1362.
45. Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E et al. Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res 2008; 68: 2436-2446.